NCT02687438View on ClinicalTrials.gov

The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Chronic Sinusitis
Interventions
DEVICE

Steroid-releasing sinus implant

PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days

OTHER

Post-op standard of care

post-op standard of care including debridement, irrigation, and/or topical steroids

Trial Locations (4)

10016

ENT and Allergy Associates, LLP, New York

10601

ENT and Allergy Associates, LLP, White Plains

11042

ENT and Allergy Associates, LLP, Lake Success

11777

ENT and Allergy Associates, LLP, Port Jefferson

Sponsors

Collaborators (1)

Intersect ENT
All Listed Sponsors
collaborator

Intersect ENT

INDUSTRY

lead

ENT and Allergy Associates, LLP

OTHER

NCT02687438 - The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery | Biotech Hunter | Biotech Hunter